Skyrizi (risankizumab) is a new biologic for treating psoriasis. The first dose in Canada was injected at Charlton Health. This treatment is given by injection as 2 prefilled syringes starting at week 0, week 4 and then every 12 weeks. It works by blocking IL-23, a cytokine that promotes production of IL-17 in skin cells. The results in achieving complete skin clearance are impressive. This is the second medication in this family of biologics.
We are always proud to be on the front lines with new treatments. Make sure to stay tuned to our #WiseWordsWednesday blog to always be kept in the loop about these new innovations.
Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.
Saphnelo (anifrolumab) is a one-of-a-kind therapy by AstraZeneca for the treatment of moderate to severe…
On December 4, 2023, Health Canada approved Pfizer’s Litfulo (ritlecitinib). Litfulo is a once-daily oral…
Infliximab is a protein-based medication referred to as a biologic that treats many immune-mediated conditions. …
On October 3rd, 2023, Health Canada approved Eli Lilly’s newest biologic for the treatment of…
As February is heart month, today is an excellent occasion to really show why we love our hearts and…
To better serve our Hamilton and area patients, we have expanded and moved our Stoney…